Pharma BD Deal Intelligence
Servier's $2.5 billion acquisition of Day One Biopharmaceuticals hands it Ojemda (tovorafenib), an approved oral brain-penetrant RAF inhibitor for pediatric low-grade glioma that directly complements Voranigo, though the ~68% premium paid signals Servier is betting heavily on pipeline extensions beyond the current label.
Servier to acquire Day One maker of pediatric cancer drug tovorafenib for $2.5B at 68 percent premium to strengthen its rare oncology leadership position.
Servier is acquiring Day One Biopharmaceuticals for $2.5 billion, making it the French pharmaceutical company's largest acquisition to date. Day One markets…
Servier's 68-86% premium signals strategic prioritization over financial restraint, particularly given tovorafenib's FDA approval, positive EU regulatory…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
Servier acquired Day One Biopharmaceuticals for approximately $2.5 billion ($21.50 per share in cash, a ~68% premium), with the transaction completed on April 23, 2026 following expiration of the tender offer on April 22, 2026 and a subsequent second-step merger; Day One was delisted from Nasdaq and became a wholly owned subsidiary of Servier. The deal gives Servier Ojemda (tovorafenib), an oral brain-penetrant RAF kinase inhibitor approved in the US for pediatric low-grade glioma and under EU review, complementing Servier's existing glioma portfolio anchored by Voranigo (vorasidenib).
25K US cases/yr · $2.7B US Market (adult malignant glioma therapeutics 2025)
Adult glioma encompasses a heterogeneous group of primary CNS tumors including glioblastoma (GBM, ~13,900 US new cases/yr; the most common malignant brain tumor) and IDH-mutant lower-grade gliomas (astrocytoma, oligodendroglioma). Outcomes are starkly bifurcated: GBM median OS remains 14-16 months despite multimodal therapy, while IDH-mutant grade 2-3 gliomas have 5-yr OS of 60-80%. Molecular stratification (IDH, 1p/19q, MGMT, BRAF) now drives treatment selection.
GBM standard of care remains surgery + radiation + temozolomide (Stupp regimen) +/- Optune TTFields; bevacizumab (Avastin) for recurrence. Voranigo (vorasidenib, Servier) was approved Aug 2024 for IDH-mutant grade 2 glioma, the first targeted therapy in this setting and a direct franchise adjacency. Late-stage pipeline includes multiple IDH inhibitors (ivosidenib/Tibsovo label expansion), CAR-T (EGFRvIII, IL13Ra2), oncolytic viruses (DNX-2401), and checkpoint combinations. ADC programs targeting EGFR, B7-H3, and HER3 are entering Phase 1/2 in recurrent glioma.
2K US cases/yr · $1.2B US Peak Sales Potential (frontline expansion)
Frontline pLGG refers to newly-diagnosed pediatric low-grade glioma patients requiring systemic therapy (those not cured by surgery alone). Historical standard of care is carboplatin/vincristine chemotherapy with ~45-50% 5-yr PFS. The field is rapidly shifting toward molecularly-targeted frontline therapy given 2-3x higher ORR with BRAF/MEK inhibitors vs chemo and durable responses in BRAF-altered disease.
No targeted agent is currently approved in frontline pLGG. All approvals (Ojemda, Tafinlar+Mekinist) are post-chemo. The Phase 3 FIREFLY-2/LOGGIC trial (tovorafenib vs SOC chemo) reads out mid-2027 and, if positive, would make Ojemda the first targeted frontline therapy with a multi-billion TAM expansion. Novartis TADPOLE (dabrafenib+trametinib frontline) is a direct competitor for the BRAF V600E subset. MEK-inhibitor frontline studies (selumetinib A071903, mirdametinib) remain in earlier phases.
2K US cases/yr · $750M US Peak Sales (Ojemda analyst consensus)
Pediatric low-grade glioma (pLGG) is the most common childhood brain tumor, representing ~30% of all pediatric CNS malignancies with ~1,900 new US cases annually (CBTRUS 2015-2019). BRAF alterations drive ~75% of cases: KIAA1549::BRAF fusions (majority) and BRAF V600E mutations (~15-17%). Long-term survival is favorable but chronic disease burden from recurrence, vision loss, and endocrine/neurologic sequelae is substantial.
Ojemda (tovorafenib, Day One/Servier) is the first pan-RAF inhibitor FDA-approved specifically for relapsed/refractory pLGG (Apr 2024) with BRAF fusion or V600 mutation; 2025 net sales $155.4M, JPMorgan peak sales estimate $750M. Tafinlar+Mekinist (dabrafenib+trametinib, Novartis) is approved for BRAF V600E pLGG. Koselugo (selumetinib, AstraZeneca) is approved in NF1 plexiform neurofibromas and widely used off-label in pLGG. Emerging: Gomekli (mirdametinib, SpringWorks) approved Feb 2025 with pLGG activity; Firefly-2 frontline tovorafenib readout mid-2027 could reset standard of care.
$24.0B Global ADC Market 2030 Forecast
Solid tumors comprise epithelial carcinomas and sarcomas across all anatomic sites that express surface antigens amenable to ADC targeting. Advanced and metastatic disease carries poor prognosis with 5-year OS typically under 20% depending on primary site and line of therapy. Tumor antigens of high interest for ADC delivery include HER2, TROP2, HER3, Nectin-4, B7-H4, PTK7, Claudin 18.2, and CDH6, chosen for differential tumor-versus-normal expression.
ADC competitive landscape is the most crowded segment in oncology: approved leaders Enhertu (AZN/Daiichi), Trodelvy (Gilead), Padcev (Pfizer/Astellas), Elahere (AbbVie), Tivdak (Pfizer/Genmab). Direct target competitors: B7-H4 - Pfizer/Seagen PF-07260437, AbbVie/ImmunoGen ABBV-514, Regeneron REGN5093-M114; PTK7 - Pfizer PF-06647020 (cofetuzumab), Merus ADC program. Platform-level peers include Pfizer/Seagen, Daiichi-Sankyo, AbbVie/ImmunoGen, Merck (Kelun-Biotech partnership), BMS (SystImmune partnership).
$10.6B US Market (ADC solid tumor segment 2030 proxy)
Advanced or metastatic solid tumors is a catch-all Phase 1 basket designation covering locally-advanced unresectable or distant-metastatic carcinomas and sarcomas across all anatomic sites. This population is the standard starting point for first-in-human oncology trials and precision-medicine umbrella studies, with typical 5-yr OS <20% depending on tumor type and line of therapy.
Competitive set depends on mechanism. The approved ADC landscape for advanced solid tumors is led by Enhertu (trastuzumab deruxtecan, AZN/Daiichi-Sankyo; $3.8B 2024), Trodelvy (sacituzumab govitecan, Gilead), Padcev (enfortumab vedotin, Pfizer/Astellas), and Elahere (mirvetuximab soravtansine, AbbVie). Pipeline: dozens of B7-H4, PTK7, TROP2, HER3, Claudin 18.2, and CDH6-directed ADCs in Phase 1-3. Immunotherapy standards (Keytruda, Opdivo, Tecentriq) compete as combo backbones and comparators in all-comer baskets.
Advanced nonhematologic malignancies is a basket classification used in early-phase oncology trials to enroll patients with any advanced/metastatic solid tumor (excluding leukemia/lymphoma/myeloma) who have exhausted standard options. Typical Phase 1 first-in-human and dose-escalation studies enroll this population to establish safety, PK, and signal-finding across tumor types before pivoting to tumor-specific expansion cohorts.
Competitive landscape is defined by the target class rather than indication. For pan-RAF agents (Ojemda/tovorafenib adult extension): competitors include Braftovi (encorafenib, Pfizer), Tafinlar (dabrafenib, Novartis), and next-gen pan-RAF/type II RAF inhibitors (exarafenib, plixorafenib). For ADC platforms (DAY301, Emi-Le): Enhertu (AZN/Daiichi), Trodelvy (Gilead), Padcev (Pfizer/Astellas), and Elahere (AbbVie) are dominant approved solid-tumor ADCs with >$10B combined run-rate.
Servier agreed to acquire Day One Biopharmaceuticals for approximately $2.5 billion ($21.50 per share in cash, a ~68% premium), gaining Ojemda (tovorafenib), an oral brain-penetrant RAF kinase inhibitor approved in the US for pediatric low-grade glioma and under EU review. The acquisition complement
Transaction between Servier Pharmaceuticals LLC and Day One Biopharmaceuticals Inc. is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Servier Pharmaceuticals LLC / Day One Biopharmaceuticals Inc. (this deal) | 2026 | $2.5B | 75 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Black Diamond Therapeutics, Inc. | 2025 | $780M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
← Browse all deals · How we score deals
More: 2026 deals · Servier Pharmaceuticals LLC deals · Oncology deals